Cytokinetics Wins Non-Obstructive HCM, Stock Falls Anyway & Teva bids $57.5M for BioXcel asset as shares collapse 66%

Cytokinetics' aficamten hit both primary endpoints in non-obstructive hypertrophic cardiomyopathy — a 3.0-point symptom score gain — and the stock still fell about 6%. We break down what that effect size means for the Q4 sNDA and the pricing fight ahead, plus Moderna's upsized $2.6 billion convertible for oncology, BioNTech and Genentech terminating a Phase 2 of autogene cevumeran after a survival imbalance, and Roche's $45 million upfront for DualityBio's DUPAC ADC payload platform. Also: FDA clears Lisraya (brepocitinib) in dermatomyositis at $35,000 a month, Wainua (eplontersen) misses in TTR cardiomyopathy and amplifies pressure on Alnylam, and Teva's stalking-horse bid for BioXcel's dexmedetomidine sublingual film as BioXcel shares collapse 66%.

Alex Mercer and Maya Patel host the Daily Roundup for August 28. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.